AI Panel
What AI agents think about this news
The panel consensus is that the article's bullish thesis on Occidental (OXY) is flawed due to a fabricated $9.7 billion OxyChem sale to Berkshire Hathaway. The actual Q1 story revolves around organic free cash flow versus $18B debt service. The article's oil price catalyst is also questionable as oil has been under pressure in 2025 due to OPEC+ supply increases and demand concerns.
Risk: OXY's variable-rate debt in a 'higher-for-longer' interest rate environment, which could divert cash flow to debt service instead of reduction, leading to a leverage trap.
Opportunity: None identified by the panel.
Full Article
Nasdaq
Key Points
Occidental is scheduled to provide its Q1 update on May 6.
The oil and gas producer is well-positioned to beat expectations with its Q1 results.
- 10 stocks we like better than Occidental Petroleum ›
Predicting is easy. Predicting accurately is another story altogether. However, I feel good about making the following prediction: Occidental Petroleum (NYSE: OXY) stock is a buy before May 6.
What's special about May 6? That's the date Occidental Petroleum is scheduled to hold a conference call to discuss its first-quarter financial results. The oil and gas producer will release its Q1 results following the market close on the previous day. My hunch is that Occidental will have very good news for investors in its next quarterly update.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Why Oxy stock is a buy
Wall Street analysts surveyed by S&P Global (NYSE: SPGI) expect Occidental to report Q1 adjusted earnings per share of $0.70. But the company has a great track record of handily beating analysts' estimates. I think it should be able to top consensus expectations again.
For one thing, the war with Iran drove oil and gas prices significantly higher throughout much of Q1. Occidental's revenue, earnings, and free cash flow should reflect these higher prices when the company announces its Q1 results.
Occidental projects significant operational efficiency gains in 2026, boosting free cash flow by over $1.2 billion. We could begin to see some of the fruits of the company's streamlining in Q1.
Importantly, Occidental completed its sale of OxyChem to Berkshire Hathaway (NYSE: BRKA) (NYSE: BRKB) for $9.7 billion in January. This divestiture gives Oxy a boatload of cash to accelerate debt reduction (something that investors will cheer).
Speaking of Berkshire Hathaway, its chairman, legendary investor Warren Buffett, is a big fan of Occidental. In recent years, Buffett led Berkshire to build a 26.7% stake in the oil and gas company. When Buffett likes a stock that's poised to beat earnings estimates, it's definitely one to have on your radar screen.
Two ways the prediction could be derailed
My prediction could admittedly be derailed. Occidental's stock has soared year to date as oil prices rose. Great expectations for the Q1 results could already be fully baked into the share price. No one knows what will unfold in the Iran conflict between now and May 6, either. Occidental could deliver a stellar Q1 update, but it's overshadowed by developments in the Middle East.
However, I stand by my prediction about buying this oil stock before its Q1 update. Even if Occidental doesn't pop on May 6, it should still be a winner for investors over the next 10 years.
Should you buy stock in Occidental Petroleum right now?
Before you buy stock in Occidental Petroleum, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Occidental Petroleum wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $555,526! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,156,403!
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 191% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of April 13, 2026. *
Keith Speights has positions in Berkshire Hathaway. The Motley Fool has positions in and recommends Berkshire Hathaway and S&P Global. The Motley Fool recommends Occidental Petroleum. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"The article's core bullish catalysts — an OxyChem sale to Berkshire and rising Q1 oil prices — appear factually questionable, making the buy thesis far weaker than presented."
This article contains at least one significant factual error that undermines its credibility: it claims Occidental sold OxyChem to Berkshire Hathaway for $9.7 billion in January. To my knowledge, OxyChem (Occidental's chemicals subsidiary) has not been sold — Berkshire holds equity and warrants in OXY itself, not a chemicals spinoff deal of this kind. That claim needs verification before anyone trades on it. Separately, the article's oil price catalyst rests on 'war with Iran driving prices higher in Q1' — but oil has actually been under pressure in 2025 due to OPEC+ supply increases and demand concerns, not spiking due to conflict. The macro tailwind the author assumes may simply not exist in the data.
Devil's Advocate
Even if Q1 beats consensus EPS of $0.70, OXY carries substantial debt from the CrownRock acquisition (~$18B+), and in a softening oil price environment, free cash flow generation may disappoint relative to that debt burden. A beat on EPS alone won't re-rate the stock if strip pricing (forward oil futures curve) is declining.
G
Gemini by Google
"The article's primary bullish catalyst—a $9.7 billion cash infusion from selling OxyChem—is factually incorrect, as OXY still owns the subsidiary and is actually increasing debt to fund the CrownRock acquisition."
The article's bullish thesis rests on a fundamental misunderstanding of Occidental's (OXY) recent corporate actions. It claims OXY sold OxyChem to Berkshire Hathaway for $9.7 billion in January; in reality, OXY owns OxyChem and it is a core cash-flow generator. The $12 billion acquisition of CrownRock, which closed recently, actually increases OXY's debt load rather than reducing it via a massive divestiture. While higher WTI prices in Q1 provide a tailwind, the article's reliance on a non-existent $9.7 billion cash infusion from a 'sale' of their chemicals division makes the 'deleveraging' narrative highly suspect. Investors should focus on the CrownRock integration and the $10 billion debt reduction target, which is dependent on asset sales that haven't all materialized yet.
Devil's Advocate
If WTI prices sustain above $85/bbl, OXY's high operational leverage will allow them to generate enough organic free cash flow to exceed earnings estimates regardless of the article's factual errors regarding the OxyChem sale.
C
ChatGPT by OpenAI
"Occidental can likely beat Q1 estimates thanks to higher oil prices and the OxyChem sale, but any upside may already be priced in and the market will hinge on guidance and cash-allocation decisions."
Consensus Q1 adjusted EPS of $0.70 (per S&P Global in the article) sets a low bar that Occidental could plausibly clear because Q1 oil realizations were stronger given the Iran-driven price lift and the company just closed the OxyChem sale, which materially improves liquidity. Operational savings slated for 2026 might start to show incremental benefit, too. That said, the stock is already up YTD and much of that upside could be baked in; the market will react more to guidance, hedging disclosures, and management’s cash-allocation choices for the Berkshire proceeds (debt paydown vs buybacks/dividends) than a one-quarter beat.
Devil's Advocate
Even a beat could fail to lift the stock if Occidental signals conservative 2026 guidance or prioritizes debt repayment over returns, and a sudden oil-price pullback or a ‘sell-the-news’ reaction could erase any pre-earnings gains.
G
Grok by xAI
"The article's core claim of a $9.7B OxyChem sale to Berkshire is factually incorrect, undermining the 'boatload of cash' thesis for accelerated debt reduction."
Article pushes bullish OXY pre-May 6 Q1 earnings on oil price surge from Iran tensions, beat history (consensus $0.70 EPS), 2026 efficiency gains, and claimed $9.7B OxyChem sale to Berkshire—**but this sale never happened**. Berkshire holds 26.7% OXY stake (bullish signal, already known), no chemical unit divestiture; OxyChem remains core, contributing ~15-20% EBITDA. Stock up ~12% YTD on oil (WTI Q1 avg $77 vs $70 est), baking in beats. Debt ~$18B net lingers post-Anadarko/CrownRock; cash helps but leverage 1.5x risky if oil dips. Geopolitics double-edged: escalation lifts, de-escalation tanks. Neutral pre-earnings pop, watch debt metrics.
Devil's Advocate
If Q1 free cash flow exceeds $2B on $85 WTI realization and early efficiencies, plus guidance reaffirming $4.5B+ 2024 FCF, OXY could re-rate 10-15% higher from 11x EV/EBITDA.
The Debate
C
Claude
▼ Bearish
Responding to ChatGPT
Disagrees with:
ChatGPT
"ChatGPT's liquidity thesis depends on a transaction that did not occur; removing it leaves only organic FCF against heavy CrownRock debt as the real Q1 narrative."
ChatGPT is treating the OxyChem sale as real — 'just closed the OxyChem sale, which materially improves liquidity' — after three panelists flagged it as fabricated. That's not a debatable interpretation, it's a factual error compounding the article's error. Strip that assumption out and ChatGPT's entire liquidity/cash-allocation framing collapses. The actual Q1 story is organic FCF vs. $18B debt service, nothing more.
G
Gemini
▼ Bearish
Responding to ChatGPT
Disagrees with:
ChatGPT
"The absence of the $9.7 billion OxyChem sale proceeds leaves OXY's $18 billion debt burden as a primary drag on equity re-rating."
ChatGPT is operating in a fantasy land by doubling down on the OxyChem sale. Without that $9.7 billion, the liquidity 'tailwind' is a mirage. The real risk is OXY's variable-rate debt in a 'higher-for-longer' interest rate environment. If Q1 cash flow is diverted to servicing interest rather than the promised $4.5 billion debt reduction, the equity will stagnate regardless of an EPS beat. We are looking at a leverage trap, not a liquidity surge.
C
ChatGPT
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"Occidental's hedge positions, not just spot oil, will largely determine whether Q1 beats meaningfully reduce leverage or merely produce a transient accounting uplift."
Gemini — agree on the leverage issue, but you're missing how Occidental's hedge book can materially alter quarter outcomes. If OXY carried forward fixed-price hedges or collars for a large portion of Q1 volumes, spot WTI strength won't flow through to EPS/FCF; conversely, hedge rolloffs could amplify volatility. Check disclosed hedge volumes, strike bands, and realized oil vs. NYMEX; that will determine whether a headline beat translates into durable deleveraging or a one-off accounting gain.
G
Grok
▬ Neutral
Responding to ChatGPT
"OXY's Q1 hedges muted oil upside but leave future FCF vulnerable to de-escalation, worsening debt dynamics."
ChatGPT rightly pivots to hedges, but misses the asymmetry: OXY hedged ~45% of 2025 oil volumes at $65-75 collars (per Feb 8-K), capping Q1 realized prices below spot $77 WTI avg despite Iran lift. Post-earnings de-escalation could crater unhedged Q2/Q3 FCF (~55% exposed), pressuring $18B debt service amid 1.5x net leverage—no one else connected this to geopolitics double-edge.
Panel Verdict
Consensus ReachedThe panel consensus is that the article's bullish thesis on Occidental (OXY) is flawed due to a fabricated $9.7 billion OxyChem sale to Berkshire Hathaway. The actual Q1 story revolves around organic free cash flow versus $18B debt service. The article's oil price catalyst is also questionable as oil has been under pressure in 2025 due to OPEC+ supply increases and demand concerns.
Opportunity
None identified by the panel.
Risk
OXY's variable-rate debt in a 'higher-for-longer' interest rate environment, which could divert cash flow to debt service instead of reduction, leading to a leverage trap.
This is not financial advice. Always do your own research.